Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives $31.00 Consensus Target Price from Analysts

Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) have been assigned a consensus recommendation of “Hold” from the eight research firms that are currently covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $31.00.

A number of research firms recently issued reports on AMPH. Barclays began coverage on Amphastar Pharmaceuticals in a research note on Tuesday, December 9th. They set an “equal weight” rating and a $30.00 price target on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a research report on Monday, December 29th. Zacks Research downgraded shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 14th. Finally, Needham & Company LLC lowered their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating on the stock in a research report on Friday, November 7th.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other news, Director Richard K. Prins sold 4,179 shares of the business’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $27.10, for a total value of $113,250.90. Following the transaction, the director owned 35,183 shares of the company’s stock, valued at approximately $953,459.30. The trade was a 10.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Floyd F. Petersen sold 2,426 shares of Amphastar Pharmaceuticals stock in a transaction on Friday, December 12th. The shares were sold at an average price of $25.92, for a total transaction of $62,881.92. Following the completion of the transaction, the director owned 71,368 shares in the company, valued at approximately $1,849,858.56. This trade represents a 3.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 18,129 shares of company stock valued at $477,176 in the last ninety days. Insiders own 27.50% of the company’s stock.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Several hedge funds have recently bought and sold shares of AMPH. Invesco Ltd. grew its holdings in Amphastar Pharmaceuticals by 28.7% in the fourth quarter. Invesco Ltd. now owns 501,404 shares of the company’s stock valued at $13,428,000 after purchasing an additional 111,811 shares during the last quarter. Vident Advisory LLC grew its position in shares of Amphastar Pharmaceuticals by 10.7% in the fourth quarter. Vident Advisory LLC now owns 20,409 shares of the company’s stock valued at $547,000 after purchasing an additional 1,978 shares during the last quarter. Fuller & Thaler Asset Management Inc. increased its stake in shares of Amphastar Pharmaceuticals by 3.0% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 1,394,463 shares of the company’s stock worth $37,344,000 after purchasing an additional 40,536 shares in the last quarter. Empowered Funds LLC raised its position in shares of Amphastar Pharmaceuticals by 10.8% during the 4th quarter. Empowered Funds LLC now owns 165,907 shares of the company’s stock worth $4,443,000 after purchasing an additional 16,112 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in Amphastar Pharmaceuticals in the 4th quarter valued at approximately $1,302,000. 65.09% of the stock is owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Stock Down 0.4%

Shares of NASDAQ:AMPH opened at $28.54 on Tuesday. The company has a current ratio of 3.12, a quick ratio of 2.21 and a debt-to-equity ratio of 0.78. The firm has a 50 day simple moving average of $27.19 and a 200-day simple moving average of $26.86. The company has a market capitalization of $1.31 billion, a PE ratio of 12.63, a P/E/G ratio of 5.23 and a beta of 0.88. Amphastar Pharmaceuticals has a twelve month low of $20.39 and a twelve month high of $32.69.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.